Navigation Links
Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
Date:3/12/2008

INDIANAPOLIS and LONDON, March 12 /PRNewswire-FirstCall/ -- Today Eli Lilly and Company announced its four-year grant of $4,384,000 to the World Health Organization (WHO) for scaling up its global capacity to manage multi- drug resistant tuberculosis (MDR-TB) programs.

The grant covers four activities, starting with the technical assistance the WHO will provide to developing countries that the Global Fund to Fight AIDS, Tuberculosis and Malaria operations do not cover. The WHO will provide assistance to some 25 countries in their clinical management of MDR-TB, infection control, laboratory facilities and community outreach. Second, the WHO will conduct workshops for health care personnel so they can better design and manage TB programs, for laboratory technicians so they can test for first and second line drug susceptibility, and for administrative personnel to record and report on TB incidence in their countries. A third component is support for training global MDR-TB experts so they can expand training in developing countries, run workshops in infection control, and strengthen laboratories for proper diagnosis and treatment. Finally, the grant will support the field-testing and evaluation of a new information system to record and report on MDR-TB rates in two countries.

"This grant represents Lilly's continued commitment to support the WHO in its goal of treating 50 million TB patients and 1.6 million MDR-TB patients by 2015. It builds upon existing WHO and Lilly program successes in curbing the MDR-TB pandemic," says Alex Azar, senior vice president of corporate affairs and communications for Lilly. "With drug resistance at an all time high, the engagement in fighting MDR-TB comprehensively is more important now than ever."

Since 2003, approximately 30,000 patients have been enrolled on treatment in WHO Green Light Committee approved projects. Country officials and healthcare personnel have consistently identified the training of human
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
2. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
3. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
4. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
5. Michael L. Eskew Elected to Lilly Board of Directors
6. Lilly Caps Successful Year with Strong Fourth-Quarter Results
7. Lilly Sets Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results Announcement
8. Lilly Announces Dividend Increase
9. Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
10. International Federation-Lilly Agreement Will Allow Significant Increase in MDR-TB Programmes
11. JDRF and Lilly partner to fund research to identify beta cell biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... MyDressCity.com, one of the most popular suppliers of wedding ... new range of elegant Quinceanera dresses . What’s ... prices. Worldwide clients can enjoy this special offer before ... shop, there are plenty of beautiful dresses for sale, ... MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, wedding ...
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... July 13, 2014 A decreased ability to ... impairment and Alzheimer,s disease, while examinations of the ... protein associated with Alzheimer,s, in the brain, according ... today at the Alzheimer,s Association International Conference 2014 ... the studies, the decreased ability to identify odors ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... (SAN DIEGO, December 11, 2011) Asymptomatic patients ... of non-Hodgkin lymphoma, have traditionally been watched for ... treated with a combination of rituximab and chemotherapy ... have suggested a role for treatment of asymptomatic ...
... is the first to systematically review and analyze the literature ... findings show a 74 percent greater risk of overdose among ... reasons for the increased risk are biological and behavioral, but ... now available online in advance of print in the journal ...
... COLLEGE PARK, Md. - Over the past decade, attacks and ... the work of extremists from across the political spectrum - ... actors - says an analysis by the National Consortium for ... at the University of Maryland. The statistics underscore the ...
... Norwegian University of Life Sciences (UMB) and Forschungszentrum Jlich ... analyses of electrical activity in the brain. The method, ... and researchers to better interpret brain cell signals. In ... terms of interpreting for example EEG measurements, making diagnoses ...
... Dec. 10 (HealthDay News) -- Giving low-dose aspirin to patients ... the lungs could cut their odds of redeveloping the clots, ... venous thromboembolisms (VTEs). These can include both the leg clots ... lungs that can cause rapid pulse, shortness of breath, chest ...
... By Steven Reinberg HealthDay Reporter , ... recommended Thursday that several newer forms of oral contraceptives ... potentially fatal blood clots. The U.S. Food ... the new labels for oral contraceptives such as Bayer,s ...
Cached Medicine News:Health News:Study favors as-needed treatment over maintenance therapy for patients with follicular lymphoma 2Health News:Study favors as-needed treatment over maintenance therapy for patients with follicular lymphoma 3Health News:RI Hospital study analyzes link between HIV infection and overdose risk 2Health News:RI Hospital study analyzes link between HIV infection and overdose risk 3Health News:Growing US violent extremism by the numbers: UMD database 2Health News:Growing US violent extremism by the numbers: UMD database 3Health News:Tapping the brain orchestra 2Health News:Low-Dose Aspirin After Lung Clot Could Prevent Recurrence 2Health News:Low-Dose Aspirin After Lung Clot Could Prevent Recurrence 3Health News:FDA Advisers: Newer Forms of the 'Pill' Need Revised Warning Labels 2Health News:FDA Advisers: Newer Forms of the 'Pill' Need Revised Warning Labels 3
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the ... direct oral once-daily Factor Xa inhibitor, significantly reduced the ... or hip arthroplasty, when compared to enoxaparin. Patients receiving ... deep vein thrombosis (DVT) and pulmonary embolism (PE) than ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), ... outsourcing company with operations in China and the United ... Science and Chemistry Awards, held on December 12, 2011 ... theme of this year,s awards was Disease Biology. Guowei ...
Cached Medicine Technology:Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 2Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 3Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 4Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 5WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 2WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 3
... the Anterior Segment The BD is optimized ... ophthalmologists specializing in the anterior segment. It is ... c-mount camera on the BD 900- may be ... in 10 and 16 X times- through the ...
... The system that makes it ... Molecular Biology Workstation is an automated ... known sequences, such as in the ... and Short Tandem Repeats (STRs) using ...
... an integrated filter made of pure ... filter provides protection against carryover and ... does not swell up as a ... then be recovered easily. In line ...
Optimized 180W Xenon lamp, low fan noise with reduced air turbulence, compact housing. Built for monitor applications and all endoscope dimensions. Ideal for video recording applications....
Medicine Products: